I'm LongbridgeAI, I can summarize articles.Puma Biotechnology reported Q2 2026 financial results, highlighting NERLYNX net revenue of USD 53.6 million, a 9% increase from Q2 2025 and 28% from Q1 2026. Ex-factory bottle sales totaled 2,929, up 12% year-over-year. U.S. commercial demand reached 2,986 bottles, rising 11% compared to the same period last year.
- Puma Biotechnology webcast on Q2 2026 financial results showed NERLYNX net revenue of USD 53.6 million. * Net revenue rose about 9% from Q2 2025, up about 28% from Q1 2026. * Inventory change was -USD 1 million in Q2 2026 versus -USD 1.3 million in Q2 2025. * Ex-factory bottles sold totaled 2,929, up about 12% from Q2 2025, up about 26% from Q1 2026. * U.S. commercial demand reached 2,986 bottles, up about 11% from Q2 2025, up about 8% from Q1 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here